Recursion (NASDAQ:RXRX) furnishes Q2-25 results materials via Form 8-K

Rhea-AI Filing Summary

Recursion Pharmaceuticals (RXRX) filed a Form 8-K dated 5 Aug 2025 to furnish its Q2-25 earnings press release and related investor materials. The filing triggers:

• Item 2.02 – Results of Operations & Financial Condition: Exhibit 99.1 contains the full press release covering quarter-end 30 Jun 2025.
• Item 7.01 – Regulation FD: Exhibits 99.2 and 99.3 provide an updated corporate deck and the presentation used during the same-day earnings call.

No financial metrics, guidance, or qualitative commentary appear in the body of the report; all substantive details reside in the furnished exhibits, which are explicitly not deemed “filed” under Exchange Act Section 18. The company remains listed on the Nasdaq Global Select Market under ticker RXRX. The document is principally procedural, confirming timely dissemination of earnings materials and incorporating the customary safe-harbor language that limits liability for furnished information.

Positive

• None.

Negative

• No financial figures are included in the 8-K body, requiring investors to retrieve separate exhibits for any substantive analysis.

Insights

Financial Analyst

TL;DR: Routine 8-K furnishes Q2 materials; no numbers disclosed, so investment impact is minimal.

This 8-K is a standard compliance filing alerting investors that Recursion’s Q2-25 results and presentations are available. Because the filing omits revenue, EPS, cash burn, or pipeline updates, the document itself offers no data to reassess valuation. The exhibits may prove material once reviewed, but the core filing only signals their release. As such, the standalone impact is neutral; market focus should shift to Exhibit 99.1 for actual performance metrics.

0001601830FALSE00016018302024-08-082024-08-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

RECURSION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40323

46-4099738

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

41 S Rio Grande Street

Salt Lake City, UT 84101

(Address of principal executive offices) (Zip code)

(385) 269 - 0203

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per share			RXRX			Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2025, the Company issued a press release announcing its results of operations and financial condition for the second quarter June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On August 5, 2025, the Company released an updated corporate presentation to the investor section of the Company’s website. A copy of the presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

Also on August 5, 2025, the Company released a presentation made in connection with its L(earnings) call on August 5, 2025. A copy of the presentation is attached hereto as Exhibit 99.3 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

The information furnished pursuant to Item 2.02 (including Exhibit 99.1) and 7.01 (including Exhibits 99.2 and 99.3) on this Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number			Description
99.1			Press release issued by the Company dated August 5, 2025
99.2			Investor presentation of Recursion Pharmaceuticals, Inc. dated August 5, 2025
99.3			L(earnings) call presentation of Recursion Pharmaceuticals, Inc. dated August 5, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on August 5, 2025.

			RECURSION PHARMACEUTICALS, INC.
			By:			/s/ Ben Taylor
						Ben Taylor
						Chief Financial Officer

FAQ

What did RXRX file on August 5, 2025?

A Form 8-K furnishing its Q2-25 earnings press release (Ex.99.1) and two investor presentations (Ex.99.2, 99.3).

Does the 8-K contain RXRX's Q2-25 revenue or EPS?

No. The filing itself includes no financial metrics; those figures are in Exhibit 99.1.

Are the furnished exhibits considered "filed" under the Exchange Act?

No. The company specifies that Exhibits 99.1-99.3 are furnished, not filed, limiting liability under Section 18.

Where can investors find the updated corporate presentation for RXRX?

It is available as Exhibit 99.2 on the company's website investor section and attached to this 8-K.

Which Nasdaq market does RXRX trade on?

RXRX is listed on the Nasdaq Global Select Market.